Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Grants Emergency Use Authorization For Anthrax Vaccine

This article was originally published in The Pink Sheet Daily

Executive Summary

The ability to opt-out of the inoculation under the Anthrax Vaccine Immunization Program is one condition of FDA’s clearance of Anthrax Vaccine Adsorbed for the prevention of inhalation anthrax. The authorization is the first use of the Emergency Use Authorization under BioShield Act of 2004.

You may also be interested in...



COVID-19 Vaccines: FDA’s Broad Authority To Craft Narrow EUAs May Push Agency Out Of Its Comfort Zone

US FDA may not be comfortable using some of the powers the emergency use authorization statute provides to limit a product’s use; regulatory distinctions for EUAs go beyond the lower ‘may be effective‘ standard needed for an authorization versus an approval. EUAs come with a lot of other tools to micromanage use that aren’t available for most approvals. 

Emergency Use Of Unapproved Drugs Outlined In FDA Draft Guidance

FDA action on requests for consideration will likely take place within hours or days in an emergency situation, according to the draft document. The agency also encourages submission of candidate products prior to an emergency “at the earliest possible time.”

Emergency Use Of Unapproved Drugs Outlined In FDA Draft Guidance

FDA action on requests for consideration will likely take place within hours or days in an emergency situation, according to the draft document. The agency also encourages submission of candidate products prior to an emergency “at the earliest possible time.”

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel